(R)-1-pyridin-3-ylbutylamine | 1213617-67-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (R)-1-pyridin-3-ylbutylamine
• 英文别名: (R)-1-(Pyridin-3-yl)butan-1-amine；(1R)-1-pyridin-3-ylbutan-1-amine
• CAS: 1213617-67-4
• 化学式: C₉H₁₄N₂
• 分子量: 150.224
• InChiKey: DFVSEQGCMQSLKO-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-(1-azidobutyl)pyridine 在 水 、 三苯基膦 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 2.0h， 生成 (1S)-1-pyridin-3-ylbutan-1-amine 、 (R)-1-pyridin-3-ylbutylamine
  参考文献：
  名称：

  Discovery of CYT997: a structurally novel orally active microtubule targeting agent

  摘要：

  CYT997 was discovered as a potent tubulin polymerization inhibitor possessing potent cytotoxic activity against a range of cancer cells. Details of SAR studies, pharmacokinetic investigations and synthesis of compounds leading to the discovery of CYT997 are reported. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.06.079

文献信息

• [EN] THERAPEUTIC COMPOUNDS AND COMPOSITIONS<br/>[FR] COMPOSÉS ET COMPOSITIONS THÉRAPEUTIQUES
  申请人：EXITHERA PHARMACEUTICALS INC

  公开号：WO2018118705A1

  公开（公告）日：2018-06-28

  The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.

  本发明提供了抑制因子XIa或激肽酶以及其药用盐和组合物的化合物。本发明还提供了使用这些化合物和组合物的方法。
• THERAPEUTIC COMPOUNDS AND COMPOSITIONS
  申请人：eXIthera Pharmaceuticals, Inc.

  公开号：US20190315711A1

  公开（公告）日：2019-10-17

  The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.
• Discovery of CYT997: a structurally novel orally active microtubule targeting agent
  作者：Christopher J. Burns、Michael F. Harte、Xianyong Bu、Emmanuelle Fantino、Max Joffe、Harrison Sikanyika、Stephen Su、C. Elisabet Tranberg、Neil Wilson、Susan A. Charman、David M. Shackleford、Andrew F. Wilks

  DOI：10.1016/j.bmcl.2009.06.079

  日期：2009.8

  CYT997 was discovered as a potent tubulin polymerization inhibitor possessing potent cytotoxic activity against a range of cancer cells. Details of SAR studies, pharmacokinetic investigations and synthesis of compounds leading to the discovery of CYT997 are reported. (C) 2009 Elsevier Ltd. All rights reserved.